Minimal prevalence of HPV vaccination and common occurrence of high-risk HPV types in pregnant women with HIV: data from a national study in Italy.
Cervical HPV
Cervical cytology
HIV
HPV types
HPV vaccination
Women
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
14
09
2021
accepted:
03
12
2021
pubmed:
10
1
2022
medline:
15
2
2022
entrez:
9
1
2022
Statut:
ppublish
Résumé
Among 733 pregnant women with HIV followed between 2013 and 2021, only 8 (1.1%) had prior HPV vaccination. One had low-grade squamous intraepithelial lesions [LSIL], and none had HPV type information. Among the 725 non-vaccinated women, 578 (79.7%) had information on cervical cytology. Rate of cytologic abnormalities in this group was 20.6% (0.2% atypical glandular cells of undetermined significance [AGC], 1.7% atypical squamous cells of undetermined significance [ASC-US], 11.1% LSIL, and 7.6% high-grade squamous intraepithelial lesions [HSIL]). Among 56 women with HPV type information, 75.0% carried high risk types, with similar occurrence in women with and without cytologic abnormalities, 30.4% had multiple high-risk types, and 75.9% carried at least one of the types included in the currently recommended 9-valent vaccine.
Identifiants
pubmed: 34999975
doi: 10.1007/s10096-021-04393-1
pii: 10.1007/s10096-021-04393-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-509Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Liu G, Sharma M, Tan N, Barnabas RV (2018) HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 32:795–808
doi: 10.1097/QAD.0000000000001765
Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah ASV et al (2021) Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 9:e161–e169
doi: 10.1016/S2214-109X(20)30459-9
Kumakech E, Berggren V, Wabinga H, Lillsunde-Larsson G, Helenius G, Kaliff M et al (2016) Significantly reduced genoprevalence of vaccine-type HPV-16/18 infections among vaccinated compared to non-vaccinated young women 5.5 years after a bivalent HPV-16/18 vaccine (cervarix) pilot project in Uganda. PLoS One 11:e0160099
doi: 10.1371/journal.pone.0160099
McClymont E, Lee M, Raboud J, Coutlée F, Walmsley S, Lipsky N et al (2019) The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus. Clin Infect Dis 68:788–794
doi: 10.1093/cid/ciy575
Canvin M, Sinka K, Hughes G, Mesher D (2017) Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect 93:125–128
doi: 10.1136/sextrans-2016-052626
Donken R, van Niekerk D, Hamm J, Spinelli JJ, Smith L, Sadarangani M et al (2021) Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: an ecological analysis on the effects of the school-based human papillomavirus vaccination program. Int J Cancer 49:191–199
doi: 10.1002/ijc.33513
Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todro T, Crepaldi A et al (2013) Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 120:1466–1475
doi: 10.1111/1471-0528.12285
Clifford GM, Tully S, Franceschi S (2017) Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis 64:1228–1235
doi: 10.1093/cid/cix135
HIV/AIDS Italian Expert Panel (2017) Linee Guida Italiane sull’utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1 Edizione 2017. Available at: https://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf . Accessed 6 Aug 2021
Ribassin-Majed L, Pereira M, Magneron C, Levy-Bachelot L, Fagherazzi G, Baldauf JJ et al (2021) Interest of a geostatistical approach to analyze the geographical disparities in human papillomavirus vaccine coverage in France. Rev Epidemiol Sante Publique 69:321–328
doi: 10.1016/j.respe.2021.09.007
Dong L, Nygård M, Hansen BT (2021) Sociodemographic correlates of human papillomavirus vaccine uptake: opportunistic and catch-up vaccination in Norway. Cancers (Basel) 13:3483
doi: 10.3390/cancers13143483
Osmani V, Klug SJ (2021) HPV vaccination and the prevention of genital warts and precancerous lesions. Current evidence and evaluation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 64:590–599
doi: 10.1007/s00103-021-03316-x
Zheng L, Wu J, Zheng M (2021) Barriers to and facilitators of human papillomavirus vaccination among people aged 9 to 26 years: a systematic review. Sex Transm Dis 48:e255–e262
doi: 10.1097/OLQ.0000000000001407
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2003) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789–1799
doi: 10.1086/657321